Valence 標誌
熱門
登入
Loading data for SLS — first visit, this takes a few seconds.

加入自選清單

SELLAS Life Sciences Grou...

NasdaqCM: SLS · 即時價格 · USD
13.21
-2.00 (-13.15%)
收盤價： Aug 28, 2026, 3:59 PM
13.47
+1.97%
盤後: 7:59 PM

股價、關鍵數字和最新消息，都在這一頁。

SELLAS Life Sciences Group Inc.（SLS）股價、分析與資料

-13.15%
買價13
市值2.67B
營收 (ttm)n/a
淨利（ttm）-32.46M
2.49
-0.19
n/a
-132.1
P/B (ttm)19.37
P/S (ttm)n/a
財報日期Nov 11, 2026
賣價13.27
成交量9,757,807
20 日平均成交量8,412,228
開盤價14.70
前收盤價15.21
當日區間13.15 - 14.79
52 週範圍1.39 - 15.88
分析師n/a
目標價n/a
股利n/a
除息日n/a

關於 SLS

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration w...

[閱讀更多]
產業 Biotechnology
類股 Healthcare
IPO 日期 Mar 12, 2008
員工 13
證券交易所 NasdaqCM
股票代號 SLS
網站 https://sellaslifesciences.com
完整的公司簡介

財務表現

SELLAS Life Sciences 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。 淨利為 -26.86M，較前期減少 -13.01%。

財務報表

財報驚奇

SELLAS Life Sciences 已於 Aug 11, 2026 公布季度財報：
  • 營收為 $0 低於預期 $0, 年增 NaN% 成長.
  • 每股盈餘為 -0.05 低於預期 -0.01, 年增 28.57% 成長.

下次財報發布

SELLAS Life Sciences Group Inc. 的下次財報預計於 Nov 11, 2026, 盤中。
分析師預估營收 ... 升級
news image

2 天前 · Insider Monkey

Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug Candidate

Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at $13.21 apiece, as investors turned increasingly concerned about the company’s silence about its tre...

news image

4 天前 · Stocktwits

SLS, IBRX Eye Fresh Oncology Tailwind As Cathie Wood’s ARK Backs Personalized Cancer-Vaccine Future

ARK sees a path toward custom cancer treatments for every patient, though current costs of $200,000-$300,000 remain a major hurdle.

news image

4 天前 · Stocktwits

Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline

On Wednesday, the U.S. Food and Drug Administration approved RASONQUE, a once-daily pill for adults with metastatic pancreatic cancer who have already tried chemotherapy or cannot take multi-drug regi...

news image

4 天前 · Stocktwits

SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon

Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.

news image

6 天前 · Stocktwits

SLS Traders Eye This Important Resistance Zone Ahead Of Key AML Data Readout

Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.

第 1 頁，共 2 頁